Topics

Genkyotex reports mixed efficacy Phase II data for PBC drug

07:11 EDT 2 May 2019 | Pharmaceutical Technology

Genkyotex has announced that its NOX1/4 inhibitor GKT831, which is indicated for primary biliary cholangitis (PBC), has met some of...
Read More...

The post Genkyotex reports mixed efficacy Phase II data for PBC drug appeared first on Pharmaceutical Technology.

Original Article: Genkyotex reports mixed efficacy Phase II data for PBC drug

NEXT ARTICLE

More From BioPortfolio on "Genkyotex reports mixed efficacy Phase II data for PBC drug"

Quick Search